Alembic Pharmaceuticals has successfully completed the United States Food and Drug Administration (USFDA) inspection for its API-III Facility located at Karakhadi. This was a scheduled GMP inspection and was successfully completed without any Form 483 observation. The inspection was conducted from March 17, 2025 to March 21, 2025.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.